» Articles » PMID: 38231444

Rescue of NLRC5 Expression Restores Antigen Processing Machinery in Head and Neck Cancer Cells Lacking Functional STAT1 and P53

Abstract

The antigen processing machinery (APM) components needed for a tumor cell to present an antigen to a T cell are expressed at low levels in solid tumors, constituting an important mechanism of immune escape. More than most other solid tumors, head and neck squamous cell carcinoma (HNSCC) cells tend to have low APM expression, rendering them insensitive to immune checkpoint blockade and most other forms of immunotherapy. In HNSCC, this APM deficiency is largely driven by high levels of EGFR and SHP2, leading to low expression and activation of STAT1; however, recent studies suggest that p53, which is often mutated in HNSCCs, may also play a role. In the current study, we aimed to investigate the extent to which STAT1 and p53 individually regulate APM component expression in HNSCC cells. We found that in cells lacking functional p53, APM expression could still be induced by interferon-gamma or DNA-damaging chemotherapy (cisplatin) as long as STAT1 expression remained intact; when both transcription factors were knocked down, APM component expression was abolished. When we bypassed these deficient pathways by rescuing the expression of NLRC5, APM expression was also restored. These results suggest that dual loss of functional STAT1 and p53 may render HNSCC cells incapable of processing and presenting antigens, but rescue of downstream NLRC5 expression may be an attractive strategy for restoring sensitivity to T cell-based immunotherapy.

Citing Articles

New insights into the structure domain and function of NLR family CARD domain containing 5.

Zhu H, Xiao C, Chen J, Guo B, Wang W, Tang Z Cell Commun Signal. 2025; 23(1):42.

PMID: 39849460 PMC: 11755879. DOI: 10.1186/s12964-024-02012-y.

References
1.
Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

2.
Zhu K, Wang J, Zhu J, Jiang J, Shou J, Chen X . p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene. 2000; 18(54):7740-7. DOI: 10.1038/sj.onc.1203235. View

3.
Youlyouz-Marfak I, Gachard N, Le Clorennec C, Najjar I, Baran-Marszak F, Reminieras L . Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ. 2007; 15(2):376-85. DOI: 10.1038/sj.cdd.4402270. View

4.
Yoshihama S, Roszik J, Downs I, Meissner T, Vijayan S, Chapuy B . NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016; 113(21):5999-6004. PMC: 4889388. DOI: 10.1073/pnas.1602069113. View

5.
De Carvalho T, de Carvalho A, Maia D, Ogawa J, Carvalho A, Vettore A . Search for mutations in signaling pathways in head and neck squamous cell carcinoma. Oncol Rep. 2013; 30(1):334-40. DOI: 10.3892/or.2013.2455. View